AR and prostate cancer: HSP90 is overexpressed in prostate cancer; co-treatment of prostate cancer cells with AR antagonist Enzalutamide and a HSP90 inhibitor induces an increased rate of cell death due to a synergistic reduction of AR protein induced by the two drugs [667].